Toxic mushrooms could help cure deadly diseases

Image
Press Trust of India Washington
Last Updated : Dec 05 2014 | 3:01 PM IST
Toxic mushrooms may hold secrets to tackling deadly diseases such as cancer, according to a new research.
A team of Michigan State University scientists has discovered an enzyme that is the key to the lethal potency of poisonous mushrooms.
The results show the enzyme's ability to create the mushroom's molecules that harbour missile-like proficiency in attacking and annihilating a single vulnerable target in the human liver.
The team unveiled how the enzyme contributes to the manufacture of chemical compounds known as cyclic peptides, a favourite type of molecule that pharmaceutical companies use to create new drugs.
These findings could lead to single-minded medicines with zero side effects, said Jonathan Walton, professor of plant biology and co-lead author.
"Mushrooms are prolific chemical factories, yet only a few of their peptides are poisonous," he said.
"These toxins survive the high temperatures of cooking and the acids of digestion, and yet they are readily absorbed by the bloodstream and go directly to their intended target. These are the exact qualities needed for an effective medicine," said Walton.
Working with the mushroom species Amanita, Walton and his teammates disassembled one of its poisonous peptides, which can be compared to a laser-guided missile with a nuclear warhead.
By removing the molecular equivalent of the deadly warhead, they now have a sturdy, precise delivery system that can supply medicine - rather than poison - to a single target.
By taking a laser, rather than a shotgun approach, scientists could develop medicines capable of curing disease without the patient suffering any side effects.
The enzyme the team discovered is called POPB, and it converts toxins from their initial linear shape into cyclic peptides, fortress-like molecular circles comprising eight amino acids.
Harnessing the distinct properties of POPB will allow scientist to create billions of variant molecules, which can be tested against many different medical targets such as pathogenic bacteria and cancer.
The study was published in the journal Chemistry and Biology.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Dec 05 2014 | 3:01 PM IST

Next Story